ACC 2022: Late-breaking Science Video Collection

Published: 05 April 2022

Views:
4069
Likes:
7

Views:
4069
Likes:
7
Share:

Now Playing
Part 4 | Session 3 of 3
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos
Erin D Michos

Up Next

Part 1 | Session 1 ACC 22 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen

Part 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up Nicolas M Van Mieghem, Joost Daemen

Part 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial Justin Ezekowitz, Harriette Van Spall

Part 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial Harriette Van Spall, Dylan L Steen

Part 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial Harriette Van Spall, Gregg C Fonarow, Tariq Ahmad

Part 2 | Session 4 ACC 22 Late-breaker Discussion: The DIAMOND Trial Harriette Van Spall, Javed Butler, Faiez Zannad

Part 3 | Session 1 ACC 22: Findings from the VALOR-HCM Trial Milind Y Desai

Part 3 | Session 2 ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten Florian Rader

Part 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial Manesh R Patel

Part 3 | Session 4 ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease Frederik Zimmermann

Part 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial Brian Bergmark

Part 3 | Session 6 ACC 22: Results from the POISE-3 Trial Philip J Devereaux

Part 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia Paolo Della Bella

Part 3 | Session 8 ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab Lorenz Räber

Part 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a) Steven E Nissen

Part 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial Maura Marcucci

Part 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials Michael J Reardon

Part 3 | Session 12 ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR Duk-Woo Park

Part 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study

Part 3 | Session 14 ACC 22: Results from the GIPS-IV Trial Pim van der Harst, Marie-Sophie de Koning

Part 3 | Session 15 ACC 22: FFR vs. IVUS-guided PCI in Intermediate Coronary Artery Stenosis: The FLAVOUR Trial Bon-Kwon Koo

Part 3 | Session 16 ACC 22: Results From the EMPULSE Study – Empagliflozin Proves Beneficial for Patients With HF Mikhail Kosiborod

Part 3 | Session 17 ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events Paul M Ridker

Part 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study Felix Mahfoud

Part 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation Michelle Kittleson

Part 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani Purvi Parwani

Part 4 | Session 2 ACC 22: 5 Trials That Will Change Your Practice with Interventionalist, Dr Mirvat Alasnag Mirvat Alasnag

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.

For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.

2 sessions
ACC 22 Late-breaking Science Preview	Watch now
ACC.22 Late-breaking Science Wrap-Up	Watch now

Part 2

Late-breaker Discussion Series

Host, Dr Harriette Van Spall interviews the late-breaker presenters of ACC Scientific Sessions 2022.

4 sessions
ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial	Watch now
ACC 2022 Late-breaker Discussion: The SuperWIN Trial	Watch now
ACC 22 Late-breaker Discussion: The PROMPT-HF Trial	Watch now
ACC 22 Late-breaker Discussion: The DIAMOND Trial	Watch now

Part 3

Expert Interviews

19 sessions
ACC 22: Findings from the VALOR-HCM Trial	Watch now
ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten	Watch now
ACC 22: Results From the PACIFIC AF Trial	Watch now
ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease	Watch now
ACC 22: Results from the TRANSLATE-TIMI 70 Trial	Watch now
ACC 22: Results from the POISE-3 Trial	Watch now
ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia	Watch now
ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab	Watch now
ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)	Watch now
ACC 22: Results From a sub-study of the POISE-3 Trial	Watch now
ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials	Watch now
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR	Watch now
ACC 22: Results From the Chocolate-Touch Study	Watch now
ACC 22: Results from the GIPS-IV Trial	Watch now
ACC 22: FFR vs. IVUS-guided PCI in Intermediate Coronary Artery Stenosis: The FLAVOUR Trial	Watch now
ACC 22: Results From the EMPULSE Study – Empagliflozin Proves Beneficial for Patients With HF	Watch now
ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events	Watch now
ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study	Watch now
2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation	Watch now

Part 4

Late-breaking Highlights

3 sessions
ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani	Watch now
ACC 22: 5 Trials That Will Change Your Practice with Interventionalist, Dr Mirvat Alasnag	Watch now
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos	Watch now

Faculty Biographies

Erin D Michos

Associate Professor of Medicine and Director of Women's Cardiovascular Health

Dr Erin Michos is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Heath and Associate Director of Preventive Cardiology with the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.

Dr Michos is an internationally known expert in Preventive Cardiology and Women’s Health and has authored over 350 publications. Her research has focused on cardiovascular disease among women; coronary artery calcium, inflammatory markers, and other novel biomarkers of cardiovascular risk; lipids; and vitamin D and other supplements. She is an Associate Editor for Circulation and the American Journal of Preventive Cardiology.

Following receipt of her medical degree from Northwestern University, Dr. Michos…

View full profile